Anticoagulant Reversal Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Anticoagulant Reversal Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Feb 2019 Transparency Market Research Healthcare156 Pages Price :
$ 5795

Global Anticoagulant Reversal Drugs Market: Overview

The global anticoagulant reversal drugs market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region, thereby presenting a thorough analysis of the overall competitive scenario in the global anticoagulant reversal drugs market. 

Global Anticoagulant Reversal Drugs Market: Key Segments

In terms of product, the global anticoagulant reversal drugs market has been segmented into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. Based on distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is anticipated to expand at a high CAGR during the forecast period. The market has been analyzed based on price variations, technology trend, and presence of key players. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Anticoagulant Reversal Drugs Market: Regional Outlook

Geographically, the global anticoagulant reversal drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles the major players in the market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key companies profiled in the global anticoagulant reversal drugs market include Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc. 

The global anticoagulant reversal drugs market has been segmented as follows:

Global Anticoagulant Reversal Drugs Market, by Product

  • Prothrombin Complex Concentrates (PCC)
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
  • Others

Global Anticoagulant Reversal Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Anticoagulant Reversal Drugs Market, by Region

  • North America
  • U.S.
  • Canada 
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe 
  • Asia Pacific
  • China
  • Japan
  • Australia
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America 
  • Middle East & Africa
  • South Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa

1. Preface 
1.1. Report Scope and Market Segmentation 
1.2. Research Highlights

2. Assumptions and Acronyms Used

3. Research Methodology

4. Executive Summary

5. Market Overview
5.1. Product Overview
5.2. Market Dynamics
5.2.1. Drivers
5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population 
5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages
5.2.1.3. NTAP status for specific drugs
5.2.2. Restraints
5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs 
5.2.2.2. Risk associated with reversing anticoagulation 
5.2.3. Opportunities
5.2.3.1. Unmet clinical needs
5.2.3.2.  Untapped market in emerging economies 
5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2016?2026
5.2.5. Global Anticoagulant Reversal Drugs Market Outlook
5.2.6. Key Industry Developments
5.2.7. Regulatory Scenario
5.2.8. Reimbursement Scenario
5.2.9. Pipeline Analysis
5.2.10. Healthcare Overview 

6. Global Anticoagulant Reversal Drugs Market Analysis, by Product 
6.1. Introduction
6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product 
6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016?2026
6.3.1. Prothrombin Complex Concentrates (PCC)
6.3.2. Vitamin K
6.3.3. Protamine
6.3.4. Tranexmic Acid
6.3.5. Idarucizumab
6.3.6. Andexxa
6.3.7. Others
6.4. Market Attractiveness, by Product 

7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel
7.1. Introduction
7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel
7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies 
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel

8. Global Anticoagulant Reversal Drugs Market Analysis, by Region
8.1. Introduction
8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific 
8.2.4. Latin America 
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Anticoagulant Reversal Drugs Market Analysis
9.1. Key Findings
9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2016?2026
9.2.1. U.S.
9.2.2. Canada
9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
9.3.1. Prothrombin Complex Concentrates (PCC)
9.3.2. Vitamin K
9.3.3. Protamine
9.3.4. Tranexmic Acid
9.3.5. Idarucizumab
9.3.6. Andexxa
9.3.7. Others
9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies 
9.4.3. Others
9.5. North America Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Product 
9.5.3. By Distribution Channel

10. Europe Anticoagulant Reversal Drugs Market Analysis
10.1. Key Findings
10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
10.2.1. U.K.
10.2.2. Germany
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
10.3.1. Prothrombin Complex Concentrates (PCC)
10.3.2. Vitamin K
10.3.3. Protamine
10.3.4. Tranexmic Acid
10.3.5. Idarucizumab
10.3.6. Andexxa
10.3.7. Others
10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies 
10.4.3. Others
10.5. Europe Market Attractiveness Analysis
10.5.1. By Country/Sub-region
10.5.2. By Product 
10.5.3. By Distribution Channel

11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis
11.1. Key Findings
11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. Australia
11.2.5. Rest of Asia Pacific 
11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
11.3.1. Prothrombin Complex Concentrates (PCC)
11.3.2. Vitamin K
11.3.3. Protamine
11.3.4. Tranexmic Acid
11.3.5. Idarucizumab
11.3.6. Andexxa
11.3.7. Others
11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies 
11.4.3. Others
11.5. Asia Pacific Market Attractiveness Analysis
11.5.1. By Country/Sub-region
11.5.2. By Product 
11.5.3. By Distribution Channel

12. Latin America Anticoagulant Reversal Drugs Market Analysis
12.1. Key Findings
12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
12.2.1. Brazil 
12.2.2. Mexico
12.2.3. Rest of Latin America
12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
12.3.1. Prothrombin Complex Concentrates (PCC)
12.3.2. Vitamin K
12.3.3. Protamine
12.3.4. Tranexmic Acid
12.3.5. Idarucizumab
12.3.6. Andexxa
12.3.7. Others
12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies 
12.4.3. Others
12.5. Latin America Market Attractiveness Analysis
12.5.1. By Country/Sub-region
12.5.2. By Product 
12.5.3. By Distribution Channel

13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
13.2.1. GCC Countries 
13.2.2. South Africa 
13.2.3. Israel 
13.2.4. Rest of Middle East & Africa
13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
13.3.1. Prothrombin Complex Concentrates (PCC)
13.3.2. Vitamin K
13.3.3. Protamine
13.3.4. Tranexmic Acid
13.3.5. Idarucizumab
13.3.6. Andexxa
13.3.7. Others
13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies 
13.4.3. Others
13.5. Middle East & Africa Market Attractiveness Analysis
13.5.1. By Country/Sub-region
13.5.2. By Product 
13.5.3. By Distribution Channel

14. Competitive Landscape
14.1. Competition Matrix
14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
14.3. Company Profiles
14.3.1. Bausch Health Companies, Inc. 
14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.1.2. Financial Overview 
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer, Inc. 
14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.2.2. Financial Overview 
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.3. Fresenius Kabi AG 
14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.3.2. Financial Overview 
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.4. Amneal Pharmaceuticals, Inc. 
14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Boehringer Ingelheim GmbH 
14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.5.2. Financial Overview 
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. CSL Limited 
14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.6.2. Financial Overview 
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.7. Octapharma AG 
14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.7.2. Financial Overview 
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.8. Portola Pharmaceuticals, Inc.
14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.8.2. Financial Overview 
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.)
14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis

List of Table

List of Tables

Table 01: Reimbursement Scenario for AndeXXa
Table 02: Reimbursement Scenario for Praxbind
Table 03: Reimbursement Scenario for Kcentra
Table 04: Pipeline Analysis
Table 05: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 06: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
Table 08: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 10: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 11: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 13: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 16: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 19: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 22: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Chart

List of Figures 

Figure 01: Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2018–2026
Figure 03: Market Value Share, by Product (2018)
Figure 04: Market Value Share, by Distribution Channel (2018)
Figure 05: Market Value Share, by Region (2018)
Figure 06: Regulatory Approval Process - U.S. 
Figure 07: Regulatory Approval Process - Europe 
Figure 08: Regulatory Approval Process - Japan
Figure 09: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2016–2026
Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2016–2026
Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2016–2026
Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2016–2026
Figure 14: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016–2026
Figure 15: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2016–2026
Figure 16: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2016–2026
Figure 17: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 18: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 19: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 20: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 21: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 22: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016–2026
Figure 23: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2017 and 2026 
Figure 24: Global Anticoagulant Reversal Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2017 and 2026
Figure 27: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2018-2026
Figure 28: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 29: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 30: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 31: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
Figure 61: Product Overview - Bausch Health Companies, Inc.
Figure 62: Breakdown of Net Sales (%), by Region, 2017 - Bausch Health Companies, Inc.
Figure 63: Revenue (US$ Mn), 2015–2017 - Bausch Health Companies, Inc.
Figure 64: R&D Expenses (US$ Mn), 2015-2017 - Bausch Health Companies, Inc.
Figure 65: Product Overview - Pfizer, Inc.
Figure 66: Breakdown of Net Sales, by Region, 2017 - Pfizer, Inc.
Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017 - Pfizer, Inc.
Figure 68: R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017 - Pfizer, Inc.
Figure 69: Product Overview - Fresenius Kabi AG
Figure 70: Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017 - Fresenius Kabi AG 
Figure 71: Breakdown of Net Sales, by Region, 2017 - Fresenius Kabi AG
Figure 72: Breakdown of Net Sales, by Segment, 2017 - Fresenius Kabi AG 
Figure 73: Research & Development Cost, 2016 - 2017 (US$ Mn) - Fresenius Kabi AG 
Figure 74: Product Overview - Amneal Pharmaceuticals, Inc.
Figure 75: Product Overview - Boehringer Ingelheim GmbH
Figure 76: Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017 - Boehringer Ingelheim GmbH 
Figure 77: Breakdown of Net Sales, by Business and Business Segment Level, 2017 - Boehringer Ingelheim GmbH 
Figure 78: Breakdown of Net Sales, by Region (Company Level), 2017 - Boehringer Ingelheim GmbH 
Figure 79: R&D Expenditure (US$ Bn), 2013–2017 - Boehringer Ingelheim GmbH 
Figure 80: Product Overview: CSL Limited
Figure 81: Total Revenue (US$ Mn) and Y-o-Y Growth, 2016–2018 – CSL Limited
Figure 82: R&D Investment, (US$ Mn) and Y-o-Y Growth, 2016–2018 - CSL Limited
Figure 83: Sales Revenue (US$ Mn) and Y-o-Y Growth, 2016–2018 - CSL Limited
Figure 84: Net Profit (US$ Mn), 2016–2018 - CSL Limited
Figure 85: Product Overview - Octapharma AG
Figure 86: Revenue (US$ Mn) and Y-o-Y Growth, 2015–2017 - Octapharma AG 
Figure 87: R&D and Selling and Marketing Expenses, (US$ Mn), 2016–2017 - Octapharma AG 
Figure 88: Year-end Employee Headcount and Y-o-Y Growth, 2015-2017 - Octapharma AG 
Figure 89: Gross profit (US$ Mn) and Y-o-Y Growth, 2016–2017 - Octapharma AG 
Figure 90: Product Overview - Portola Pharmaceuticals, Inc.
Figure 91: R&D and Selling and Marketing Expenses, (US$ Mn), 2016–2017 - Portola Pharmaceuticals, Inc. 
Figure 92: Revenue (US$ Mn) and Y-o-Y Growth, 2015–2017 - Portola Pharmaceuticals, Inc. 
Figure 93: Product Overview - Perosphere Pharmaceuticals Inc.

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 5795
$ 8795

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top